Clinical Trials Browser

Phase 1 × INDUSTRY × cediranib × Clear all

NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT00621725 2014-07-15

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Phase 1 Completed

Neoplasm Metastasis

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

Phase 1 Completed

19 enrolled 7 charts

Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00621361 2012-12-17

Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients

Phase 1 Completed

Lung Neoplasms

NCT00502567 2011-07-27

A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT00748891 2011-07-01

DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)

Phase 1 Completed

Neoplasms

NCT00981721 2011-06-20

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Phase 1 Completed

Advanced Solid Malignancies

NCT00960349 2011-06-14

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Phase 1 Completed

Gastrointestinal

Stomach Neoplasms

NCT00539331 2011-06-01

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT00750425 2011-03-10

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Completed

Neoplasm Metastasis

NCT00501605 2011-01-21

Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT00502164 2011-01-21

AZD2171IL/0003

Phase 1 Completed

Advanced Prostate Adenocarcinoma

NCT00502385 2011-01-21

Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML

Phase 1 Completed

Other hematologic neoplasm

Leukemia

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Neoplasms

NCT00503477 2009-06-12

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT00502060 2009-05-14

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

Phase 1 Completed

Advanced Tumor

NCT00503412 2009-01-19

Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

Phase 1 Completed

Neoplasm Metastasis